Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. (15th January 2014)

• Record Type: Journal Article
• Authors: Patrick, Katharine; Wade, Rachel; Goulden, Nicholas; Rowntree, Clare; Hough, Rachael; Moorman, Anthony V; Mitchell, Christopher D; Vora, Ajay
• Is Part Of: British journal of haematology. Volume 165:Number 4(2014:May)
• Page Start: 552
• Page End: 555
• Publication Date: 2014-01-15
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12739
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh12739-abs-0001"> <title>Summary</title> <p>We report the outcome for children and young people with Down syndrome‐associated acute lymphoblastic leukaemia (DS‐ALL) treated on a contemporary protocol. Compared with non‐DS ALL, patients with DS‐ALL had an inferior event‐free survival (65·6% vs. 87·7% at 5 years; <italic>P </italic>&lt;<italic> </italic>0·00005) and overall survival (70·0% vs. 92·2%; <italic>P </italic>&lt;<italic> </italic>0·00005). Excess treatment‐related mortality – was primarily responsible for the worse outcomes for DS‐ALL (21·6% at 5 years, vs. 3·3%, <italic>P </italic>&lt;<italic> </italic>0·00005). Minimal residual disease (MRD) risk status was highly discriminant for relapse in DS patients with 0/28 relapses in the MRD low risk group.</p> </abstract>